Summary
Intuitive Surgical Inc. (ISRG) reported strong financial performance for the nine months ended September 30, 2015, with total revenue reaching $1.7 billion, a 12% increase year-over-year. This growth was driven by a robust increase in da Vinci procedures, up 14% globally, with particularly strong performance in general surgery and urology. The company's recurring revenue stream, which includes instruments, accessories, and service, continues to be a significant contributor, making up 71% of total revenue for the period. Net income for the nine months increased to $398.8 million from $272.0 million in the prior year, reflecting improved operational efficiencies and a lower effective tax rate. The company also maintained a strong cash position, ending the period with $3.1 billion in cash, cash equivalents, and investments. Despite the positive financial results, investors should note ongoing product liability litigation, which has resulted in significant charges in prior periods and may continue to pose a risk. The company also highlighted challenges related to currency fluctuations, particularly the strengthening U.S. dollar, which negatively impacted reported revenue. The company continues to invest in research and development, with R&D expenses increasing by 11% year-over-year, signaling a commitment to innovation and future product development, including the ongoing rollout of the da Vinci Xi Surgical System.
Financial Highlights
46 data points| Revenue | $589.70M |
| Cost of Revenue | $193.90M |
| Gross Profit | $395.80M |
| R&D Expenses | $51.00M |
| SG&A Expenses | $154.90M |
| Operating Expenses | $205.90M |
| Operating Income | $189.90M |
| Net Income | $167.30M |
| EPS (Basic) | $0.50 |
| EPS (Diluted) | $0.49 |
| Shares Outstanding (Basic) | 335.70M |
| Shares Outstanding (Diluted) | 342.00M |
Key Highlights
- 1Total revenue for the first nine months of 2015 increased by 12% to $1.7 billion, compared to $1.5 billion in the same period of 2014.
- 2Da Vinci procedures grew by 14% globally for the nine months ended September 30, 2015.
- 3Recurring revenue, comprising instruments, accessories, and service, accounted for 71% of total revenue, amounting to $1.2 billion for the nine months ended September 30, 2015.
- 4Net income for the nine months ended September 30, 2015, rose to $398.8 million, a significant increase from $272.0 million in the prior year.
- 5The company's cash, cash equivalents, and investments grew to $3.1 billion as of September 30, 2015.
- 6Selling, general, and administrative expenses decreased by 10% year-over-year for the nine months ended September 30, 2015, primarily due to lower product liability settlement charges.
- 7Research and development expenses increased by 11% to $144.8 million for the nine months ended September 30, 2015, reflecting continued investment in innovation.